167 related articles for article (PubMed ID: 35228944)
1. Hereditary Coproporphyria Mimicking Guillain-Barré Syndrome After COVID-19 Infection.
Upchurch M; Donnelly JP; Deremiah E; Barthol C; Hafeez S; Anderson KE; Seifi A
Cureus; 2022 Jan; 14(1):e21586. PubMed ID: 35228944
[TBL] [Abstract][Full Text] [Related]
2. A Case of Hereditary Coproporphyria in which the Patient's Course Improved after the Discontinuation of Givosiran.
Ozaki N; Hayashi Y; Kiyota A
Intern Med; 2024 Mar; ():. PubMed ID: 38462517
[TBL] [Abstract][Full Text] [Related]
3. Acute porphyrias - A neurological perspective.
Gerischer LM; Scheibe F; Nümann A; Köhnlein M; Stölzel U; Meisel A
Brain Behav; 2021 Nov; 11(11):e2389. PubMed ID: 34661997
[TBL] [Abstract][Full Text] [Related]
4. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.
Sardh E; Harper P
J Intern Med; 2022 May; 291(5):593-610. PubMed ID: 35067977
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial.
Kuter DJ; Bonkovsky HL; Monroy S; Ross G; Guillén-Navarro E; Cappellini MD; Minder AE; Hother-Nielsen O; Ventura P; Jia G; Sweetser MT; Thapar M;
J Hepatol; 2023 Nov; 79(5):1150-1158. PubMed ID: 37479139
[TBL] [Abstract][Full Text] [Related]
6. Case Report: Lack of Response to Givosiran in a Case of ALAD Porphyria.
Graff E; Anderson KE; Levy C
Front Genet; 2022; 13():867856. PubMed ID: 35991568
[No Abstract] [Full Text] [Related]
7. Neurology of the acute hepatic porphyrias.
Oliveira Santos M; Leal Rato M
J Neurol Sci; 2021 Sep; 428():117605. PubMed ID: 34375916
[TBL] [Abstract][Full Text] [Related]
8. Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.
Wang B; Ventura P; Takase KI; Thapar M; Cassiman D; Kubisch I; Liu S; Sweetser MT; Balwani M
Orphanet J Rare Dis; 2022 Aug; 17(1):327. PubMed ID: 36028858
[TBL] [Abstract][Full Text] [Related]
9. Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP).
Massachi S; Epstein J; Hurd J; Bonkovsky HL
J Med Econ; 2020 Dec; 23(12):1441-1449. PubMed ID: 33043761
[TBL] [Abstract][Full Text] [Related]
10. Acute hepatic porphyrias: Identification of 46 hydroxymethylbilane synthase, 11 coproporphyrinogen oxidase, and 20 protoporphyrinogen oxidase novel mutations.
Loskove Y; Yasuda M; Chen B; Nazarenko I; Cody N; Desnick RJ
Mol Genet Metab; 2019 Nov; 128(3):352-357. PubMed ID: 30385147
[TBL] [Abstract][Full Text] [Related]
11. Givosiran: A Review in Acute Hepatic Porphyria.
Syed YY
Drugs; 2021 May; 81(7):841-848. PubMed ID: 33871817
[TBL] [Abstract][Full Text] [Related]
12. Preventing hyperhomocysteinemia using vitamin B
Redonnet-Vernhet I; Mercié P; Lebreton L; Blouin JM; Bronnimann D; Mesli S; Guibet C; Ribeiro E; Gensous N; Duffau P; Gouya L; Richard E
Mol Genet Metab Rep; 2024 Jun; 39():101076. PubMed ID: 38601120
[TBL] [Abstract][Full Text] [Related]
13. Guillain-Barre Syndrome in a Patient With COVID-19 Infection.
Sidhom F; Sandhu H
Cureus; 2021 Aug; 13(8):e17052. PubMed ID: 34522530
[TBL] [Abstract][Full Text] [Related]
14. Hepatic porphyria: A narrative review.
Arora S; Young S; Kodali S; Singal AK
Indian J Gastroenterol; 2016 Nov; 35(6):405-418. PubMed ID: 27796941
[TBL] [Abstract][Full Text] [Related]
15. Acute Porphyrias.
Besur S; Schmeltzer P; Bonkovsky HL
J Emerg Med; 2015 Sep; 49(3):305-12. PubMed ID: 26159905
[TBL] [Abstract][Full Text] [Related]
16. Givosiran to treat acute porphyria.
Honor A; Rudnick SR; Bonkovsky HL
Drugs Today (Barc); 2021 Jan; 57(1):47-59. PubMed ID: 33594389
[TBL] [Abstract][Full Text] [Related]
17. Guillain-Barre Syndrome following SARS-COVID-19 Infection: A Case Report from India.
Singhai A; Budhiraja A
Case Rep Infect Dis; 2021; 2021():4676659. PubMed ID: 34136292
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.
Ventura P; Bonkovsky HL; Gouya L; Aguilera-Peiró P; Montgomery Bissell D; Stein PE; Balwani M; Anderson DKE; Parker C; Kuter DJ; Monroy S; Oh J; Ritchie B; Ko JJ; Hua Z; Sweetser MT; Sardh E;
Liver Int; 2022 Jan; 42(1):161-172. PubMed ID: 34717041
[TBL] [Abstract][Full Text] [Related]
19. High penetrance, recurrent attacks and thrombus formation in a family with hereditary coproporphyria.
Towns C; Balakrishnan S; Florkowski C; Davies A; Barrington-Ward E
JIMD Rep; 2022 May; 63(3):211-215. PubMed ID: 35433170
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
